Growth Factors-Loaded Temperature-Sensitive Hydrogel as Biomimetic Mucus Attenuated Murine Ulcerative Colitis via Repairing the Mucosal Barriers.
Dingwei LiJianxun ShangguanFengnan YuGaolong LinHanxiao PanMengjiao ZhangHaoran LinBen ChenHe-Lin XuSunkuan HuPublished in: ACS applied materials & interfaces (2024)
The pathogenesis of ulcerative colitis (UC) is associated with the shedding of the gut mucus. Herein, inspired by the biological functions of mucus, growth factors-loaded in situ hydrogel (PHE-EK) was designed for UC treatment by integrating dihydrocaffeic acid-modified poloxamer as a thermosensitive material with hyaluronic acid (colitis-specific adhesive), epigallocatechin-3-gallate (antibacterial agent), and bioactive factors (KPV tripeptide and epidermal growth factor). PHE-EK presented good thermosensitive properties, as a flowable liquid at room temperature and gelled within 10 s when exposed to body temperature. PHE-EK hydrogel presented good mechanical strength with a strain of 77.8%. Moreover, PHE-EK hydrogel displayed antibacterial activity against Escherichia coli . Importantly, in vitro and in vivo adhesive tests showed that the PHE-EK hydrogel could specifically adhere to the inflamed colon via electrostatic interaction. When PHE-EK as a biomimetic mucus was rectally administrated to colitis rats, it effectively hindered the body weight loss, reduced the disease activity index and improved the colonic shorting. Moreover, the expression of pro-inflammatory cytokines (e.g., IL-1β, IL-6, and TNF-α) at the laminae propria or epitheliums of the colon for colitis rats was substantially inhibited by PHE-EK. Besides, the colonic epitheliums were well rearranged, and the tight junction proteins (Zonula-1 and Claudin-5) between them were greatly upregulated after PHE-EK treatment. Collectively, PHE-EK might be a promising therapy for UC.
Keyphrases
- ulcerative colitis
- hyaluronic acid
- drug delivery
- wound healing
- tissue engineering
- growth factor
- disease activity
- room temperature
- rheumatoid arthritis
- escherichia coli
- weight loss
- systemic lupus erythematosus
- cancer therapy
- type diabetes
- poor prognosis
- cystic fibrosis
- ionic liquid
- multidrug resistant
- pseudomonas aeruginosa
- anti inflammatory
- juvenile idiopathic arthritis
- combination therapy
- staphylococcus aureus
- molecular dynamics simulations
- candida albicans
- weight gain